Ultragenyx Pharmaceutical Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy RARE?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding setrusumab (UX 143) during Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices.
- Potential Losses: The lawsuit claims that while setrusumab increases bone density, it does not correlate with a decrease in annualized fracture rates, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosures.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, urging investors to be cautious in selecting legal counsel.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.500
Low
35.00
Averages
61.65
High
120.00
Current: 23.500
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding setrusumab (UX 143) during Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices.
- Potential Losses: The lawsuit claims that while setrusumab increases bone density, it does not correlate with a decrease in annualized fracture rates, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosures.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, urging investors to be cautious in selecting legal counsel.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a securities fraud class action lawsuit for actions taken between August 3, 2023, and December 26, 2025, with investors having until April 6, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that the company misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the Phase III Orbit study's potential failure to achieve a statistically significant reduction in annualized fracture rate, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities and reputational damage the company may face due to these allegations.
- Legal Process: Investors can apply to be lead plaintiffs by April 6, 2026, or choose to remain absent class members, illustrating the complexities and potential impacts of legal proceedings on investor rights and company operations.
See More
Class Action Lawsuit Announced Against Ultragenyx Pharmaceutical Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, alleging that the company concealed critical information regarding clinical trial results, leading shareholders to buy at inflated prices.
- Compensation Mechanism: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, significantly reducing the financial burden on participants in the class action.
- Details of the Lawsuit: The lawsuit claims that Ultragenyx made false statements regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, asserting that while the drug increased bone density, it did not correlate with a decrease in fracture rates, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its expertise and experience in handling such cases.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study's results, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff in the case, indicating the urgency and importance of investor participation in the legal process for potential recovery.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx Pharmaceutical Class Action Update
- Lawsuit Timeline: Robbins Geller law firm announced that purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock must seek lead plaintiff status by April 6, 2026, providing a clear legal framework for investors to act.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period from August 3, 2023, to December 26, 2025, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) study, misleading investors about the company's prospects.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; further, on December 29, 2025, the announcement of study failures led to an additional 42% drop, reflecting extreme market pessimism regarding the company's future.
- Lead Plaintiff Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, allowing them to represent other investors in the lawsuit and providing an opportunity for potential recovery.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta (OI) patients, leading to an erroneous optimistic outlook among investors and impacting market confidence.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate (AFR) in the Phase III ORBIT study, revealing the falsity and misleading nature of its public statements, which resulted in investor losses once the truth was disclosed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
Ultragenyx Pharmaceutical Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ultragenyx (NASDAQ:RARE) common stock between August 3, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding setrusumab (UX 143) during Phase III Orbit and Cosmic studies, leading investors to purchase shares at artificially inflated prices.
- Potential Losses: The lawsuit claims that while setrusumab increases bone density, it does not correlate with a decrease in annualized fracture rates, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosures.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating a strong track record and extensive experience, urging investors to be cautious in selecting legal counsel.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is facing a securities fraud class action lawsuit for actions taken between August 3, 2023, and December 26, 2025, with investors having until April 6, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that the company misled investors by failing to disclose risks associated with its drug setrusumab, particularly regarding the Phase III Orbit study's potential failure to achieve a statistically significant reduction in annualized fracture rate, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, highlighting the potential financial liabilities and reputational damage the company may face due to these allegations.
- Legal Process: Investors can apply to be lead plaintiffs by April 6, 2026, or choose to remain absent class members, illustrating the complexities and potential impacts of legal proceedings on investor rights and company operations.
See More
Class Action Lawsuit Announced Against Ultragenyx Pharmaceutical Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Ultragenyx Pharmaceutical stock between August 3, 2023, and December 26, 2025, alleging that the company concealed critical information regarding clinical trial results, leading shareholders to buy at inflated prices.
- Compensation Mechanism: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, significantly reducing the financial burden on participants in the class action.
- Details of the Lawsuit: The lawsuit claims that Ultragenyx made false statements regarding the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, asserting that while the drug increased bone density, it did not correlate with a decrease in fracture rates, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its expertise and experience in handling such cases.
See More
Ultragenyx Pharmaceutical Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who purchased securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of False Statements: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study's results, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff in the case, indicating the urgency and importance of investor participation in the legal process for potential recovery.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, underscoring its expertise in upholding market integrity and investor rights.
See More
Ultragenyx Pharmaceutical Class Action Update
- Lawsuit Timeline: Robbins Geller law firm announced that purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock must seek lead plaintiff status by April 6, 2026, providing a clear legal framework for investors to act.
- False Statement Allegations: The lawsuit alleges that Ultragenyx and its executives made false or misleading statements during the class period from August 3, 2023, to December 26, 2025, failing to disclose risks associated with their Osteogenesis Imperfecta (OI) study, misleading investors about the company's prospects.
- Stock Price Volatility: Following the July 9, 2025, announcement that the Phase III Orbit study failed to achieve statistical significance, Ultragenyx's stock plummeted over 25%; further, on December 29, 2025, the announcement of study failures led to an additional 42% drop, reflecting extreme market pessimism regarding the company's future.
- Lead Plaintiff Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Ultragenyx stock during the class period can seek lead plaintiff status, allowing them to represent other investors in the lawsuit and providing an opportunity for potential recovery.
See More
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, urging affected investors to contact the firm before April 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Ultragenyx made false and misleading statements regarding its understanding of the effects of its drug candidate on Osteogenesis Imperfecta (OI) patients, leading to an erroneous optimistic outlook among investors and impacting market confidence.
- Clinical Trial Failure: The company failed to achieve a statistically significant reduction in annualized fracture rate (AFR) in the Phase III ORBIT study, revealing the falsity and misleading nature of its public statements, which resulted in investor losses once the truth was disclosed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, showcasing the firm's expertise in representing investors in securities class action lawsuits globally.
See More
